Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-11-13
DOI
https://doi.org/10.1200/jco-26-01039
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index

Jack Khouri, Mahmoud Gaballa, Luciano J. Costa, Faiz Anwer et al.
8 links
Journal of Clinical Oncology
Multiple Myeloma Research and Treatments
article

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index

Jack Khouri, Mahmoud Gaballa, Luciano J. Costa, Faiz Anwer, Aimaz Afrough, Saad Z. Usmani, Christen M. Dillard, Eli Zolotov, Jana Mihályová, Yi Lin, Surbhi Sidana, Efstathios Kastritis, Frederick Lundry Locke, Rahul Kumar Banerjee, Darren Pan, Danai Dima, Hitomi Hosoya, Shaji Kunnathu Kumar, Jeries Kort, Andrew Jay Portuguese, Gliceida Galarza Fortuna, Shahzad Raza, Joaquín Martínez‐López, Lekha Mikkilineni, Hossam M. Ali, Cindy Varga, Larry Don Anderson, Leyla Osman Shune, Utkarsh Goel, Shebli Atrash, Omar Alexis Castaneda Puglianini, Doris K. Hansen, Murali Janakiram, Noa Biran, Hamza Hassan, Hira S. Mian, Aishwarya Sannareddy, Douglas Weston Sborov, Sireesha Asoori, Krina K. Patel, Kelley L. Julian, Peter Michael Voorhees, Oren Pasvolsky, Kimberly M Green, Chiung‐Yu Huang, Saurabh Zanwar, Rachid Baz, Thomas G Martin, Megan M. Herr, Masooma Shifa Rana, Christopher James Ferreri, Emily C. Liang, Lauren Cole Peres, Rakesh Popat, Ariel Felipe Grajales-Cruz, Susan Bal, James A. Davis, Melissa Alsina, Carlyn Rose C. Tan, Andre De Menezes Silva Corraes, Mrugakshi Dave, Amrita Y. Krishnan, Lisa Lee, Raffaela Cassano Cassano, Tiffany Richards, Binod Dhakal
article en

Abstract

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.

Journal of Clinical Oncology
Roswell Park Comprehensive Cancer Center (US), City Of Hope National Medical Center (US), Cleveland Clinic (US), Hackensack University Medical Center (US), Mayo Clinic (US), Memorial Sloan Kettering Cancer Center (US), University College London Hospitals NHS Foundation Trust (GB), The University of Texas MD Anderson Cancer Center (US), Medical University of South Carolina (US), University of California, San Francisco (US), University of Ostrava (CZ), National and Kapodistrian University of Athens (GR), University of Utah (US), Juravinski Cancer Centre (CA), Huntsman Cancer Institute (US), Moffitt Cancer Center (US), University of Alabama at Birmingham (US), University Hospital Ostrava (CZ), Fred Hutch Cancer Center (US), Spanish National Cancer Research Centre (ES), Levine Cancer Institute (US), City of Hope (US), Birmingham VA Medical Center (US), University of Kansas Medical Center (US), Stanford Medicine (US), International Myeloma Foundation (US), UCSF Helen Diller Family Comprehensive Cancer Center (US), Wake Forest University (US), The University of Texas Southwestern Medical Center (US), Stanford University (US), McMaster University (CA)
Good health and well-being
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon